**Table S4.** Univariate analyses of factors that influenced Atezolizumab + Bevacizumab conversion therapy.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **Category** | **No. of Patients (%)** | | **Univariate** |
| **Atezo+Bev**  **Conversion +** | **Atezo+Bev**  **Conversion**  **-** | **p-value** | |
| Age, (years) | ≥75  <75 | 4 (67)  2 (33) | 49 (48)  58 (52) | 0.42 | |
| Sex | Male  Female | 4 (67)  2 (33) | 93 (87)  14 (13) | 0.20 | |
| Etiology | Viral  No-viral | 4 (67)  2 (33) | 52 (52)  55 (48) | 0.10 | |
| ECOG PS | 1  0 | 1 (17)  5 (83) | 24 (22)  83 (85) | 1 | |
| mALBI Grade 1+2a | Yes  No | 6 (100)  0 (0) | 58 (54)  49 (46) | 0.03 | |
| Child-Pugh score 5 | Yes  No | 1 (17)  5 (83) | 39 (36)  68 (64) | 0.42 | |
| BCLC stage | B  C | 5 (83)  1 (17) | 60 (56)  57 (44) | 0.16 | |
| AFP level (ng/mL) | ≥400  <400 | 1 (17)  5 (83) | 38 (36)  69 (64) | 0.66 | |
| Treatment line | First line | 5 (83) | 65 (61) | 0.41 | |
|  | Later line | 1 (17) | 42 (39) |  | |